🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

RecruitingPhase 4Ages 18 Years - 75 YearsAllChina National Center for Cardiovascular Diseases
NCT06096909 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 18 to 75 years; * clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ; * undergoing PCI * baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina. Exclusion Criteria: * Severe heart failure (Killip III or IV) or cardiogenic shock; * Previous hemorrhagic cerebrovascular disease history; * Uncontrolled or recurrent arrhythmic events; * poorly controlled hypertension; * Severe hepatic and renal insufficiency (ALT/AST\> 3 times upper limit of normal, eGFR\<30 ml/kg/1.73m2, or ongoing dialysis) or creatine kinase elevation\>5 times upper limit of normal * malignant tumor; * Intolerance to statins or cholesterol absorption inhibitors; * Intolerance to injections; * Life expectancy \<1 year; * poor compliance.
💊

What it tests

  • Tafolecimab
  • Cholesterol Absorption Inhibitor
  • Statin
📍

Where

2 sites
Fuwai Hospital
Beijing, China
Tangshan Central Hospital
Tangshan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy